{"id":"NCT00427921","sponsor":"Abbott","briefTitle":"Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)","officialTitle":"A Multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2007-01-29","resultsPosted":"2009-10-23","lastUpdate":"2009-11-20"},"enrollment":304,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To make adalimumab available to subjects suffering from moderately to severely active Crohn's Disease (CD) and to expand the safety information on adalimumab. The study also assessed changes in Patient Reported Outcome Measures from baseline.","primaryOutcome":{"measure":"Mean Extent of Exposure - Duration in Days","timeFrame":"Up to 24 weeks","effectByArm":[{"arm":"40 mg Adalimumab Every Other Week","deltaMin":159.2,"sd":34.78}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.humira.com/"]},"adverseEventsSummary":{"seriousAny":{"events":44},"commonTop":["Crohn's Disease","Abdominal pain","Injection site reaction","Nausea","Headache"]}}